Results 31 to 40 of about 2,026 (172)

Psychedelic Psychotherapy: Building Wholeness Through Connection

Global Advances in Health and Medicine, 2022
Background We are confronted with dire statistics that document our current mental health crisis. New treatment modalities are desperately needed to address escalating mental suffering and trauma.
Gita Vaid MD, Barry Walker MEd
doaj   +1 more source

Cyberdelics in context: On the prospects and challenges of mind-manifesting technologies

Frontiers in Psychology, 2023
The concept of cyberdelics emerged in the 1980s and 1990s as an umbrella term denoting the nexus connecting cybernetic (digital) technologies and psychedelic (mind manifesting) drugs.
Ido Hartogsohn
doaj   +1 more source

Medical student attitudes and perceptions of psychedelic-assisted therapies

Frontiers in Psychiatry, 2023
IntroductionAlthough certain psychedelic agents may soon gain federal approval for use in treating specific psychiatric conditions, the utilization of such therapies in clinical practice will depend largely on the attitudes of healthcare providers ...
Irene Li, Rodney Fong, Molly Hagen, Molly Hagen, Burton Tabaac, Burton Tabaac   +5 more
doaj   +1 more source

Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders. [PDF]

ACS Med Chem Lett
Sabnis RW, Sabnis AR.
europepmc   +2 more sources

The association between naturalistic use of psychedelics and co-occurring substance use disorders

Frontiers in Psychiatry, 2023
ObjectiveClassic psychedelics (LSD, psilocybin, and peyote/mescaline) have been used to support addiction treatment in a variety of contexts ranging from ceremonial use to clinical trials.
Jonina Rabinowitz, Shaul Lev-Ran, Shaul Lev-Ran, Shaul Lev-Ran, Raz Gross, Raz Gross, Raz Gross   +6 more
doaj   +1 more source

A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

Frontiers in Pharmacology, 2021
5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes.
Johannes Reckweg, Natasha L. Mason, Cees van Leeuwen, Stefan W. Toennes, Theis H. Terwey, Johannes G. Ramaekers   +5 more
doaj   +1 more source

Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective

Frontiers in Psychiatry, 2023
The efficacy of psilocybin and other psychedelics as modes of treatment have been demonstrated through clinical trials and other studies in the management of a number of mental illnesses, including some treatment resistant cases.
Winston De La Haye, Geoffrey Walcott, Jordan Eaton, Jhoelle Beckford, Janelle Greene   +4 more
doaj   +1 more source

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

Molecules, 2022
The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic
Henry Lowe, Ngeh Toyang, Blair Steele, Justin Grant, Amza Ali, Lorenzo Gordon, Wilfred Ngwa   +6 more
doaj   +1 more source

This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience

Frontiers in Psychology, 2023
IntroductionMuch research has focused on the modeling of the near-death experience (NDE) by classical and atypical psychedelics; however, to date, no study has reported on the relationship between the NDE and the experience induced by the highly potent ...
Pascal Michael, David Luke, David Luke, Oliver Robinson   +3 more
doaj   +1 more source

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice

Translational Psychiatry, 2022
Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through mechanisms which are incompletely understood.
Christopher W. Thomas, Cristina Blanco-Duque, Benjamin J. Bréant, Guy M. Goodwin, Trevor Sharp, David M. Bannerman, Vladyslav V. Vyazovskiy   +6 more
doaj   +1 more source